SPACs focused on healthcare and biotech are increasing in number thanks to the bullish stock market and the pandemic, but market saturation lurks around the corner, reports Modern Heatlhcare. Read more (paywall).
Related Posts
SPACs in Space: Report
2020 and 2021 brought a new wave of space companies going public, often by way of a SPAC, reports Private Equity News.
How SPAC Insiders Make Millions While Later Investors Struggle: Analysis
Investors who bought into a SPAC that took a healthcare-services company public last year in an $11 billion deal have suffered steep losses, reports Private Equity News. But promoters of the SPAC still stand to make millions.
More Unicorns Boarding SPAC Train: Report
Taking a unicorn public almost always involved a traditional IPO or direct listing. But in recent quarters, a once-obscure option — a SPAC merger — has become an increasingly mainstream alternative, Crunchbase reports
Palantir Failed to Spot Pattern in SPAC Debacle
Realized and unrealized losses on the SPAC portfolio reached 75% at the end of September, or about $333 million, according to an analysis of Palantir’s latest accounts. The red ink may have increased since then.